Webinar: Challenges and opportunities in Peptide Drug Conjugates (PDCs)
PDCs have gained extensive attention as they are being proven successful in treating cancers recently with their superior target-specific delivery. Here we discuss how we overcome challenges and demonstrate opportunities through case studies.
Case Study: PDC Drug R&D and Manufacturing in 9 Months
The integrated peptide platform of WuXi STA offered parallel streamlines which enabled this PDC project completed in 9 months
WuXi TIDES Brochure: CRDMO platform for Oligonucleotide, Peptide and Complex Conjugate
WuXi TIDES Oligonucleotide, Peptide & Complex Conjugates Business Introduction
White paper: Picking the right cdmo partner for integrated and accelerated peptide therapeutic development
Protein therapeutics have played an important role in medicine since the advent of insulin therapy to treat diabetes in the 1920s. More recently, peptides have emerged as valuable therapeutics with attractive drug properties.
A case study: An integrated peptide development enables IND submission in 10 months
A 12-minute webinar presented by Pete Nguyen, Ph.D., Director Business Development Oligo/Peptide, WuXi STA